RMJ Holdings LLC (RMJH) is a private Limited Liability Company with a mission to develop promising repurposed drug candidates and to license them to well-funded alliance partners for commercialization, marketing and sales.
The initial RMJH development focus is hypertension with a ‘first in class’ high value treatment. RMJH-111b is a post phase 2, phase 3 ready de-risked drug candidate. The novelty includes a patented inverted micellar technology to enhance uptake and target delivery of magnesium, an essential yet often deficient cell mineral. RMJH-111b is the first novel approach to manage hypertension in decades, combining technology with novel chemistry. Additional drug indications form a platform in cardiovascular medicine as well as offering an additional pipeline of drug indications described below. RMJH is utilizing the 505(b)(2) pathway for speed and economy.